Navigation Links
Genoptix Reports Strong Financial Results For Third Quarter 2007
Date:12/12/2007

239 127 191 99

Diluted 1,674 127 1,635 99

Pro forma net income (loss) per

share (2):

Basic $0.32 $(0.07) $0.77 $(0.31)

Diluted $0.28 $(0.07) $0.68 $(0.31)

Shares used to compute pro forma net

income (loss) per share (2):

Basic 11,271 11,159 11,223 11,131

Diluted 12,772 11,159 12,728 11,131

(1) For purposes of calculating net income per share for the three and

nine months ended September 30, 2007, we first allocated $3,485 of our

net income and $8,522 of our net income, respectively, to preferred

stockholders pursuant to the rights of these preferred stockholders,

resulting in $102 and $157, respectively, of net income allocable to

common stockholders for such periods.

(2) The pro forma net income (loss) per share information assumes the

conversion of all outstanding shares of preferred stock upon the

completion of the IPO as if such conversion had occurred as of the

beginning of each period presented.

GENOPTIX, INC.

PRO FORMA NET INCOME (LOSS) PER SHARE (1)

(in thousands, except per share data)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Numerator:

Net income (loss) $3,587 $(771) $8,679 $(3,401)

Denominator:

Weighted average shares of common

stock outstanding 318 181 249 160

Weighted avg un
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Genomics and Proteomics Analytical Instruments Market ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the ... is the study of the structure and functions of ... and bioinformatics tools and technology. Genomics involves the mapping ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... 1, 2011 Tengion, Inc. (Nasdaq: TNGN ), ... entered into definitive agreements with certain investors in connection with ... Securities Act of 1933, as amended.  Medtronic (NYSE: ... the financing and, as part of its investment, secured a ...
... Wash., March 1, 2011 Iverson Genetic Diagnostics, Inc. announced ... dverse Event R eduction f or A ... itiation) was initiated at WellStar Health System in Marietta and ... genetic testing to determine a personalized warfarin dose for individual ...
... gold particles are currently intensively investigated for possible ... and molecular electronics. The particles are prepared in ... gold cores can be stabilised with various organic ... using organothiolate ligands that have a strong chemical ...
Cached Biology Technology:Tengion Announces Pricing of $31.4 Million Private Placement 2Tengion Announces Pricing of $31.4 Million Private Placement 3WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 4Fingerprints of a gold cluster revealed 2
(Date:7/23/2014)... DIEGO , July 24, 2014 Pfenex Inc. ... public offering of 8,333,333 shares of its common stock at ... addition, Pfenex has granted the underwriters a 30-day option to ... the initial public offering price. The shares are expected to ... under the symbol "PFNX". William Blair ...
(Date:7/23/2014)... Children who have been abused or neglected early ... emotional and physical health problems. In a new ... way genes are activated, which has implications for ... a particular child,s individual characteristics and genetics interacted ... understand how health problems emerge. In the new ...
(Date:7/23/2014)... In Aesop,s fable about the crow and the pitcher, a ... he tries to drink from it, he finds the water ... over the pitcher, the bird drops pebbles into it ... enough for him to drink his fill. , Highlighting the ... often be more effective than brute force. It also characterizes ...
Breaking Biology News(10 mins):Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4
... EAST LANSING, Mich. A repellant for sea lampreys could ... destructive invasive species in the Great Lakes, says a Michigan ... cues have on lampreys. When scents from dead sea lampreys ... efforts to escape are dramatic. In the past, these reactions ...
... used to the fact that most new-born foals suffer from ... including supplementing the mothers, diets with -carotene, which is known ... However, Juliane Kuhl in the group of Christine Aurich at ... this food supplement has no real effect on the incidence ...
... led by Professor Malcolm McConville from the Bio21 Institute, University ... used for many infectious parasites and bacteria. The technique has ... down to the particular atoms it uses as a food ... field because the more we know about these dangerous pathogens ...
Cached Biology News:Sea lampreys fear the smell of death 2No treatment is the best treatment -- diarrhea in young foals 2
... The Polymerase gene from Thermus aquaticus ... in E. coli, then highly purified ... is used in the amplification and ... The quality of the Taq DNA ...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 5,000 units polymerase, ...
Rabbit polyclonal to hnRNP-U...
... is an antibody-mediated hot-start DNA ... and real-time PCR applications. The ... concentration of 5 units per ... polymerase, 1.25 ml 10x PCR ...
Biology Products: